May 22, 2020 - 9:00am

,

Agenda

Meeting Information:
Due to the COVID-19 pandemic, this meeting will be conducted online virtually using Microsoft Teams only. To access meeting, click here.

Registration required to attend. To register, click here.

1. Call to order
2. Approval of minutes from January 24, 2020 (vote required)
3. Announcement: Drug Utilization Review Board Conflict of Interest Policy Review
4. New business:

   Public comment on drug classes to be reviewed for the Medicaid (PDL):

   1. Anti-allergens, oral
   2. Antibiotics, inhaled
   3. Anticoagulants
   4. Antidepressants, other
   5. Antidepressants, selective serotonin reuptake inhibitors
   6. Antidepressants, tricyclic
   7. Antihyperuricemics
   8. Antiparkinsons agents
   9. Antivirals, oral/nasal
   10. Anxiolytics
   11. Beta blockers
   12. Bile salts
   13. Benign prostatic hyperplasia treatments
   14. Bronchodilators, beta agonist
   15. Chronic obstructive pulmonary disease agents
   16. Cough and cold agents
   17. Erythropoiesis stimulating proteins
   18. Glucagon agents
   19. Glucocorticoids, inhaled
   20. Hereditary angioedema treatments
   21. Immune globulins, intravenous
   22. Immunomodulators, asthma
   23. Lincosamides/oxazolidinones/streptogramins
   24. Lipotropics, other
   25. Lipotropics, statins
   26. Pulmonary arterial hypertension agents, oral and inhaled
   27. aa. Pancreatic enzymes
   28. bb. Pediatric vitamin preparations
   29. cc. Prenatal vitamins
   30. dd. Sedative hypnotics
   31. ee. Sickle cell anemia treatments
   32. ff. Thrombopoiesis stimulating proteins 
   33. gg. Urea cycle disorder, oral
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid preferred drug list:
   1. Absorica LD (oral) / Acne agents, oral
   2. Reyvow (oral) / Antimigraine agents, other
   3. Ubrelvy (oral) / Antimigraine agents, other
   4. Secuado (transdermal) / Antipsychotics agents
   5. Gabacaine Kit (miscellaneous) / Neuropathic pain agents
   6. Ziextenzo syringe (subcutaneous) / Colony stimulating
6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
7. Executive work session

   Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
9. Retrospective DUR:  Mariya Baranova, Pharm. D., MCMP-II, Conduent, LLC
   1. Report on recent retrospective DUR interventions:
      1. Prevention of adverse drug events in patients receiving opioids
      2. Pain management with opioids
      3. Monitoring of psychotropic drugs in youth
   2. Report on recent retrospective DUR intervention outcomes:
      1. Psychotropic drugs in adults
      2. Medication adherence
      3. Mental health disorder therapy management
      4. Respiratory disease management
   3. Retrospective DUR proposals (vote required)
      1. Asthma
      2. Nonsteroidal anti-inflammatory drugs (NSAIDS)
      3. Post-traumatic stress disorder (PTSD)
10. Prospective prior authorization proposals (clinical edits):  Christina Faulkner, Pharm. D., BCPS, KEPRO, LLC (vote required)
    1. Monoclonal antibody agents for asthma - new criteria
    2. Ophthalmic immunomodulators - new criteria
    3. Transthyretin agents - new criteria
    4. Tricyclic antidepressants - new criteria
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program:  Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Benzodiazepines (not including sedative/hypnotics)
    2. Complement inhibitor and enzyme/protein replacement therapy
    3. Direct oral anticoagulants
    4. Hydroxy-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors
    5. Low-molecular-weight heparins
    6. Nebulized bronchodilators
12. Next meeting date: July 24, 2020
13. Adjourn

Contact:  Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O Castoreno, DUR/Formulary Support Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-552-7672 or VDP-Advisory@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/meetings.

This meeting is open to the public.  Registration is required, as noted above, but there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-552-7672 at least 72 hours before the meeting so appropriate arrangements can be made.